We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

You Can't 'Patent Dance' Your Way Out Of Biosimilar Notice

Law360, New York (July 7, 2016, 11:57 AM EDT) -- Tasha M. Francis

Jenny A. Shmuel On July 5, 2016, the Federal Circuit issued its decision in Amgen Inc. v. Apotex Inc. affirming the district court’s ruling that notice of commercial marketing under the Biologics Price Competition and Innovation Act is only effective after U.S. Food and Drug Administration approval of a biosimilar, even when the parties engage in the so-called “patent dance.” This is the second panel of the Federal Circuit to interpret the BPCIA as requiring notice after FDA licensure, dealing a blow to biosimilar applicants...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.